Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | BCL2 | P10415 | 4/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 4/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.43 |
| ▸ | BCL2A1 | Q16548 | 4/20 | 0.43 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7462647 | 0.88 | TACR1 (0.52) | NPC1RAB9AROCK2LMNASMN1; SMN2 | |
| SCHEMBL7182884 | 0.82 | NPC1 (0.48) | NPC1RAB9AMAPTTP53ROCK2 | |
| SCHEMBL6241847 | 0.82 | HSD17B10 (0.53) | RAB9ATP53LMNASMN1; SMN2 | |
| SCHEMBL6881357 | 0.80 | ALDH1A1 (0.54) | NPC1TP53ROCK2ROCK1LMNA | |
| SCHEMBL2481230 | 0.79 | NPC1 (0.67) | NPC1RAB9AMAPTTP53LMNA | |
| SCHEMBL5709362 | 0.79 | NPC1 (0.67) | NPC1RAB9AMAPTTP53LMNA | |
| SCHEMBL6760861 | 0.78 | HDAC3 (0.41) | MAPTLMNA | |
| SCHEMBL5847828 | 0.77 | HDAC6 (0.53) | RAB9ALMNASMN1; SMN2 | |
| SCHEMBL5846615 | 0.75 | CTSD (0.45) | MAPTLMNA | |
| SCHEMBL7145325 | 0.74 | NPC1 (0.67) | NPC1RAB9ATP53LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020032174-A1 | Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2002-03-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032174-A1 | Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade | TFPI, PLAT, TFPI2 | NPC1 4227/4885RAB9A 4120/4885MAPT 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.